Edmonton, 18 June 2024 – Innovotech Inc. (TSX-V: IOT) reports the publication of “Antiviral Activity of Ag5IO6, A Unique Silver Compound” in the Special Issue of Viruses entitled “Impact of Co-Infections in COVID-19: Predisposing Mechanisms and Interplay between Invasive Viral, Bacterial, and Fungal Pathogens” (Viruses 2024, 16(6), 959, https://doi.org/10.3390/v16060959).
The reported study shows that Innovotech’s InnovoSIL™-1 silver periodate, originally developed for its broad-spectrum antimicrobial activity, including antibiofilm activity, has demonstrated rapid virucidal activity against norovirus and two strains of the SARS-CoV-2 virus.
In vitro testing following ASTM E1052-20 (Standard Practice to Assess the Activity of Microbicides Against Viruses in Suspension), showed that InnovoSIL™-1 silver was able to generate total kill of the omicron strain of COVID-19 within 30 minutes, as well as total kill of murine norovirus and the original COVID-19 strain within four hours.
Based on its performance in this study, it is anticipated that InnovoSIL™-1 silver would also be effective against viruses such as influenzas, herpes simplex virus 1 (HSV-1), and respiratory syncytial viruses (RSVs). The study showed low activity against adenovirus and no measurable antiviral activity against poliovirus.
InnovoSIL™-1 silver’s antiviral properties are broadly efficacious in wound dressings and medical devices, as well as new potential applications, such as coatings on touch surfaces or incorporation into air filters. In addition, these properties uniquely position InnovoSIL™-1 silver for situations where either infection prevention or simultaneous treatment of microbes (bacteria or fungi) and viruses are desirable.
Innovotech would like to acknowledge Alberta Innovates’ support for this research through an AICE-Validates grant.
